-
公开(公告)号:US20090238883A1
公开(公告)日:2009-09-24
申请号:US12298883
申请日:2007-04-27
CPC分类号: A61K48/005 , A61K47/61 , A61K47/62 , A61K47/6907 , A61K48/0008 , B82Y5/00
摘要: This disclosure describes liver-specific nanocapsules for specifically targeting liver cells. This disclosure also provides methods of using such liver-specific nanocapsules to deliver one or more cargo moieties to the liver cells.
摘要翻译: 本公开描述了用于特异性靶向肝细胞的肝特异性纳米胶囊。 本公开还提供了使用这种肝特异性纳米胶囊将一个或多个货物部分递送至肝细胞的方法。
-
公开(公告)号:US20120058180A1
公开(公告)日:2012-03-08
申请号:US13221552
申请日:2011-08-30
IPC分类号: A61K9/51 , A61K38/48 , A61K38/37 , A61K31/713 , A61P1/16 , A61P3/00 , A61P7/00 , A61P31/14 , A61P37/00 , A61P11/00 , A61P35/00 , A61K31/711 , A61P7/04 , B82Y5/00
CPC分类号: A61K48/005 , A61K47/61 , A61K47/62 , A61K47/6907 , A61K48/0008 , B82Y5/00
摘要: This disclosure describes liver-specific nanocapsules for specifically targeting liver cells. This disclosure also provides methods of using such liver-specific nanocapsules to deliver one or more cargo moieties to the liver cells.
摘要翻译: 本公开描述了用于特异性靶向肝细胞的肝特异性纳米胶囊。 本公开还提供了使用这种肝特异性纳米胶囊将一个或多个货物部分递送至肝细胞的方法。
-
公开(公告)号:US06524613B1
公开(公告)日:2003-02-25
申请号:US09108006
申请日:1998-06-30
IPC分类号: A61K9127
CPC分类号: C12Q1/6883 , A61K48/0008 , A61K48/005
摘要: The present invention concerns compositions and methods for the introduction of specific genetic changes in endogenous genes of the cells of an animal. The genetic changes are effected by oligonucleotides or oligonucleotide derivatives and analogs, which are generally less than about 100 nucleotides in length. The invention provides for macromolecular carriers, optionally incorporating ligands for clathrin coated pit receptors. In one embodiment the ligand is a lactose or galactose and the genetic changes are made in hepatocytes. By means of the invention up to 40% of the copies of a target gene have been changed in vitro. Repair of mutant genes having a Crigler-Najjar like phenotype and Hemophilia B phenotype were observed.
摘要翻译: 本发明涉及用于在动物细胞的内源基因中引入特异性遗传变化的组合物和方法。 遗传变化由寡核苷酸或寡核苷酸衍生物和类似物(其长度通常小于约100个核苷酸)来实现。 本发明提供大分子载体,任选地引入用于网格蛋白涂覆的凹坑受体的配体。 在一个实施方案中,配体是乳糖或半乳糖,并且在肝细胞中产生遗传变化。 通过本发明,靶基因的多达40%的拷贝在体外已被改变。 观察到具有Crigler-Najjar样表型和血友病B表型的突变基因的修复。
-
公开(公告)号:US06544972B1
公开(公告)日:2003-04-08
申请号:US09509309
申请日:2000-08-15
IPC分类号: A61K3156
CPC分类号: A61K31/575 , A61K31/353
摘要: Methods for limiting apoptosis in a cell population by contacting such cells with a hydrophilic bile acid, such as ursodeoxycholic acid (UDCA), salts thereof, and analogs thereof (e.g., glyco- and tauro-ursodeoxycholic acid).
摘要翻译: 通过使这种细胞与亲水性胆汁酸(例如熊去氧胆酸(UDCA)),其盐及其类似物(例如糖和牛磺熊去氧胆酸)接触来限制细胞群中细胞凋亡的方法。
-
-
-